Table 5.
Characteristics of NHL patients > age 65 years undergoing autologous HCT from 1990 to 2000 and reported to the CIBMTR.
| Variable | N (%) |
|---|---|
| Number of patients | 149 |
| Age, median (range), years | 67 (65 – 73) |
| Male sex | 71 (48) |
| Karnofsky performance score at transplant | |
| <90 | 61 (41) |
| ≥ 90 | 87 (59) |
| Missing | 1 |
| Histology | |
| Follicular grade I/II | 21 (14) |
| Follicular grade III DLBCL/Immunoblastic NHL | 128 (86) |
| Disease stage at diagnosis | |
| I or II | 59 (40) |
| III or IV | 87 (58) |
| Unknown | 3 (2) |
| B symptoms at diagnosis | |
| Absent | 91 (61) |
| Present | 40 (27) |
| Unknown | 18 (12) |
| Disease status at transplant | |
| CR1 | 10 (7) |
| CR2+ | 33 (24) |
| PIF-sensitive | 18 (13) |
| PIF-resistant | 2 (1) |
| REL-sensitive | 48 (35) |
| REL-resistant | 15 (11) |
| REL-untreated/unknown | 13 (9) |
| Missing | 10 |
| Chemosensitivity at transplant | |
| Sensitivity | 109 (73) |
| Resistant | 24 (16) |
| Untreated/not evaluable/unknown | 16 (11) |
| Interval from diagnosis to transplant | |
| <12 months | 34 (23) |
| ≥12 months | 115 (77) |
| Graft type | |
| Bone marrow | 17 (11) |
| Peripheral blood | 132 (89) |
| Use of involved-field radiation | 6 (4) |
| Use of TBI | 19 (13) |
| Year of transplantation | |
| 1990–1994 | 21 (14) |
| 1995–1996 | 32 (22) |
| 1997–1998 | 54 (36) |
| 1999–2000 | 42 (28) |
| In vitro purging performed | 10 (7) |
| G-CSF or GM-CSF to promote engraftment | 134 (90) |
| New malignancy | |
| Solid tumor | 3 (2) |
| Skin cancer | 1 (1) |
| New malignancy, not specified | 5 (3) |
| None | 140 (94) |
| Median follow-up of survivors, months | 69 (3 – 139) |
Abbreviations: CR = Complete Remission; PIF=primary induction failure TBI = Total Body Irradiation; GF = growth factors; G-CSF = granulocyte-colony stimulating factor; GM-CSF = granulocyte-macrophage colony stimulating factor.